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Abstract:  
 
Methamphetamine (meth) and amphetamine are commonly abused central nervous 
system (CNS) stimulants that are frequently screened for in many forensic and clinical 
toxicology labs. Amphetamine is present as the metabolite of methamphetamine, but also 
maybe be taken directly. These drugs exist in two chiral forms, d- and l-, called 
enantiomers. d-Meth is physiologically more reactive in the CNS, affecting the dopamine 
system and making it more likely to be abused. l-Meth is commonly found in nasal 
decongestants, as it has more peripheral nervous system (PNS) effects and less CNS 
stimulant effects than d-meth. For these reasons, d-meth is commonly abused and 
obtained illegally, while l-meth may be legally obtained in over the counter (OTC) nasal 
decongestant products. 
 
Most drug testing laboratories used liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) to confirm the presence of methamphetamine and 
amphetamine, but this doesn’t typically differentiate between the enantiomers. As there is 
utility in understanding whether the methamphetamine in a urine specimen is from a licit 
or illicit source, it would be useful to develop screening methods that can differentiate 
between the d- and l- enantiomers in forensic and clinical toxicology labs.  
 
In this research, a simple and cost-effective LC-MS/MS chiral separation method was 
developed to separate d- and l-enantiomers of methamphetamine and amphetamine. 
Separation methods using a chiral column with either solid phase extraction or dilute and 
shoot specimen preparation were developed and successfully applied to research 
specimens. The differentiation of enantiomers using an achiral column and a pre-column 
derivatization with Marfey’s reagent was also researched, but the derivatives were 
challenging to detect in the LC-MS/MS. The successful chiral column extraction methods 
were applied to five (5) anonymized urine samples in a single-blind test, four negatives 
and one positive for methamphetamine, and it was possible to identify both d-
methamphetamine and d-amphetamine. 
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CHAPTER I 
 
 
I. INTRODUCTION 
 
 The great opioid epidemic has gained significant national attention, with the number of 
associated deaths soaring to over 70,000 in 2015.1 However, another drug quietly hangs back in 
the shadows of the opioid problem: methamphetamine. In 2015, nearly 4,900 methamphetamine 
users died from an overdose in the United States.1 This represents a 35 % increase of meth-related 
deaths in just one year. In 2014, the number of meth-related deaths was 3,728, which is more than 
double the 1,388 methamphetamine deaths in 2013.2-3 In Oklahoma, 271 meth-related deaths 
occurred in 2015; that number increased to 328 in 2016.2 
 Methamphetamine, or meth, and amphetamine are drugs that are commonly encountered 
and screened for in many forensic and clinical toxicology labs. These drugs are chiral 
compounds, or a pair of compounds that are non-superimposable mirror images of each other.4 
Both meth and amphetamine have two optical forms, d- and l-, called enantiomers. The structures 
of the d- and l-enantiomers of amphetamine and meth are shown in Figures 1 and 2, respectively.5 
2 
 
 
Figure 1: Structures of d- and l-amphetamine enantiomers5 
 
Figure 2: Structures of d- and l-meth enantiomers5 
 As seen in the above figures, enantiomers are compounds that have the same physical and 
chemical properties, but the body will react differently depending on the enantiomeric form.4 The 
d-form of meth is more effective in the central nervous system, where it causes the release of 
dopamine, as well as blocking its reuptake, and is five times more physiologically reactive than 
the l-form.4 This is why illicit meth that is purchased on the street will more often contain the d-
form. The l-form of meth is the less reactive form of the two forms and is the active ingredient in 
over-the-counter nasal decongestant medicines, like Vicks VapoInhalerTM. 
 The separation and quantification of meth and amphetamine enantiomers is not a new 
problem in forensic and clinical toxicology labs. Many labs will employ analytical techniques that 
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will detect the presence or absence of meth and/or amphetamine but will not distinguish between 
either enantiomer for either drug. These techniques usually only identify whether a screened 
sample is positive or negative for the presence of meth and/or amphetamine. If an analyzed 
sample is positive for meth and/or amphetamine, labs may be requested to further test the sample 
to identify which isomer is present to differentiate illicit use from legal or licit use.  
 In cases where a lab does not have a chiral separation method in place, the sample will 
need to be sent out to an off-site lab for the chiral analysis. However, the process of sending these 
positive samples to another lab for the separation analysis can get quite expensive. For these 
reasons, toxicology labs may need to develop techniques for the enantiomeric separation of meth 
and amphetamine on-site. 
 The main separation techniques currently employed in forensic and clinical toxicology 
labs involve gas chromatography (GC) and liquid chromatography (LC) coupled with mass 
spectrometry (MS).4,6-8 GC-MS methods often require the addition of a chiral derivatization 
reagent, that is added to a sample to modify the analyte to make it more stable for analysis. The 
reagents are added to the enantiomers during sample preparation to form diastereomers prior to 
analysis.4,6,9-10  
 Diastereomers are a pair of non-super imposable mirror images of a compound that are 
formed during sample preparation for analysis of meth or amphetamine enantiomers. The chiral 
derivatization reagent must be a detector-sensitive compound for the type of analytical technique 
to be used in order to be effective.9 By employing derivatization of a compound, the sensitivity 
and selectivity of the chemically modified sample will be increased.10 Examples of chiral 
derivatization reagents include: 1-(9-fluorenyl)ethyl chloroformate (l-FLEC)4, 1-fluoro-2,4-
dinitrophenyl-5-L-alanine amide (Marfey’s reagent)4,9, 9-fluorenylmethyl chloroformate-L-
proline (FMOC-L-Pro)4, and o-phthalaldehyde (OPA).4,9   
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 However, additions of chiral reagents can affect the overall percentages of meth and 
amphetamine enantiomers in samples of suspected abusers. GC-MS not only causes racemization, 
but also lengthens the sample preparation time prior to analysis.6 Racemization is a chemical 
process where a drug will undergo a reaction to result in an equal mixture of each possible 
enantiomer. Racemization occurs, for example, when a sample of pure d-meth undergoes 
derivatization and a mixture of both d- and l-forms of meth are present in the sample.  
 The combination of LC combined with tandem mass spectrometry detectors (LC-
MS/MS) is commonly employed in forensic and clinical toxicology labs due to its ability to 
detect very low amounts of drugs and substances in samples. LC-MS/MS has many advantages 
when compared to GC-MS for separation of enantiomers. LC-MS/MS requires less sample 
preparation time prior to analysis. This technique can also lead to more accurate results because 
racemization of enantiomers is not as likely to occur during the analytical procedure since 
derivatization is not employed.6 
 The existing literature shows three main methods that are employed for the separation of 
drug enantiomers: use of a chiral selector that acts as an additive in the mobile phase, use of a 
chiral column, or the addition of a chiral derivatization reagent to a sample to form diastereomers 
for analysis on an achiral column.4 There are many published LC methods using chiral columns 
to separate meth and amphetamine enantiomers.5-6,11-12 
 A chiral column eliminates the need for pre-column derivatization of a sample because 
enantiomers will react differently with the internal environment of the column for separation of 
the enantiomers to occur.8 The Astec ChirobioticTM column has been established to effectively 
separate and quantify both meth and amphetamine enantiomers in common forensic and clinical 
toxicology samples, including blood, urine, and hair.5,7,12-13 However, a major disadvantage with  
chiral columns is that they are often very expensive. Many forensic and clinical toxicology labs 
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may have strict budgets or do not have funds to purchase these columns, so labs need to find less 
expensive options to separate enantiomers.  
 A more viable option for enantiomeric separation is for labs to add a chiral derivatization 
reagent to the sample during the pre-column derivatization process, which is a more cost-effective 
option when compared to the chiral column. Marfey’s reagent is one such chiral derivatization 
reagent that has been proven to be effective in the chiral separation of meth and amphetamine 
enantiomers.4,7,14-15 
 The analysis of specific enantiomers can provide law enforcement, forensic and clinical 
toxicology labs with useful information, such as to the location from which meth and/or 
amphetamine end products originated. Analysis of a drug’s enantiomers can also provide helpful 
information as to what the identity of the starting materials that were used for a specific drug 
production-method were.16 Determination of the enantiomers may also provide law enforcement 
information about the manufacturing process and the precursor sources used to make the end 
products, as pseudoephedrine results in d-meth and phenylacetone results in a racemic mixture of 
d- and l-meth.4  
 The purpose of this research was to develop a simple and cost-effective chiral separation 
method to separate d- and l-meth and amphetamine in urine samples using LC-MS/MS. Two 
separation methods using an Astec Chirobiotic chiral column were developed, as well as an 
additional method that attempted to use Marfey’s chiral derivatization reagent on an achiral 
column. 
 As a result of this research, forensic and clinical toxicology labs will be able to determine 
the appropriate separation analyses of meth and amphetamine enantiomers. The more effective 
chiral separation method may enable those labs to save money by not having to send out positive 
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meth and/or amphetamine urine samples to an off-site lab for the enantiomeric separation 
analysis.
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CHAPTER II 
 
 
II. LITERATURE REVIEW 
 
2.1. Overview 
 Methamphetamine, or meth, and amphetamine are central nervous system (CNS) 
stimulants that are classified as phenethylamine compounds.  Other drugs in this class include 
3,4-methylenedioxymethamphetamine (MDMA), 3,4-Methylenedioxy-N-ethylamphetamine 
(MDEA), 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxyamphetamine (HMA), 
ephedrine (EPH), and pseudoephedrine (PSE).7-8,17 Meth and amphetamine are highly abused 
drugs that can either be inhaled, injected, ingested, or snorted.  
 These highly abused drugs have some therapeutic uses. Both meth and amphetamine are 
used in the treatment of narcolepsy, attention deficit disorder (ADD) and attention deficit 
hyperactivity disorder (ADHD), obesity, and depression.7,16-17 Meth can also be found in the 
prescription drug Desoxyn, which is used to treat asthma.7 Both meth and amphetamine are chiral 
compounds that have two optical forms, d- and l-, called enantiomers. These can be separated 
using chiral columns or with a chiral derivatization reagent that forms diastereomers, which are 
compounds that can easily be separated, prior to analysis. 
 A review of the literature demonstrates that meth and amphetamine are complex drugs 
with a long history of abuse. There are many published studies on the separation and 
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quantification of d- and l-enantiomers of meth and amphetamine using chiral columns and pre-
column derivatization with chiral derivatization reagents in blood, urine, plasma, oral fluid, and 
hair.13,18 However, a comparison study of the separation of d- and l-meth and amphetamine 
enantiomers using two different chiral separation methods in urine samples is still lacking. 
 The goal of this chapter is to provide the reader with an overview of meth and 
amphetamine. The history, illegal production methods of meth and amphetamine, the definition 
and importance enantiomers will be discussed. Analytical methods and extraction methods that 
are commonly used in forensic and clinical toxicology labs to separate and quantify drug 
enantiomers will also be discussed. 
2.2. History of Methamphetamine and Amphetamine 
 Meth was first created in Japan in 1893,7 while amphetamine first appeared in 1877.17 
The use of meth and amphetamine became popular during World War II, when the military used 
amphetamine as stimulants to keep personnel awake and alert for prolonged combat periods.16,18 
It was also common for bomber pilots and their crews to frequently take amphetamine pills to 
keep themselves alert on long bombing missions.19  
 During the Gulf War, d-amphetamine pills were given to pilots to combat fatigue during 
long flights.16 Amphetamine was also given to helicopter pilots during periods of sleep 
deprivation to improve their alertness.16 Military personnel used meth to increase a soldier’s 
endurance and suppress appetite during combat.7  
 After the war the use and abuse of both meth and amphetamine grew to be so large that in 
1970, Congress passed the Controlled Substances Act. This law introduced a scheduling system 
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that placed various drugs of abuse into categories I-V, based on the drug’s medical value, 
harmfulness to the user and the environment, and its potential for dependence and/or misuse and 
abuse.7,17,20 Schedule I drugs, like heroin and marijua, have no accepted medical value but a high 
potential for abuse.20 Schedule II drugs, such as meth and amphetamine, have a high potential for 
abuse and dependence but some therapeutic uses.7,17,20 Prescription drugs are classified as 
Schedule III-V drugs; these drugs can be obtained through prescription refills.20 
2.3. Illegal Production of Methamphetamine and Amphetamine 
 As the United States government placed new rules and regulations on methamphetamine 
and amphetamine use, illegal laboratories and production methods emerged. One illegal 
production method uses phenylacetone as the starting material.7,16-17 This method is called the 
P2P method, in which phenylacetone is combined with methylamine and reduced to result in a 
50/50 mixture of d- and l-meth.   
 The United States government eventually classified phenylacetone as a Schedule II drug 
due to its use in the illegal production of meth.17 As a result, meth cooks had to find new starting 
materials to use to produce meth. Ephedrine and pseudoephedrine, common ingredients found in 
prescription cold medicines, became those new starting materials. With these new starting 
materials, new illegal production methods emerged: the Red Phosphorous and Birch reduction 
methods. The Red Phosphorous method involves the reduction of l-ephedrine or d-
pseudoephedrine with hydroiodic acid and red phosphorous acid to reduce the starting molecules 
to result in pure d-meth. 7,16-17 Red phosphorous can be obtained from common materials such as 
matchbook striker plates, while hydroiodic acid can be created from iodine. 7,16 The Birch 
reduction method uses the same starting materials as the Red Phosphorous method, with lithium 
metal in liquid ammonia to result in pure d-meth.7 Lithium metal can be obtained from lithium 
batteries, and ammonia from agricultural sources.7 Phenylpropanolamine can be substituted as the 
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starting material for either the Red Phosphorous or Birch reduction methods to result in d-
amphetamine instead of meth.16 
 In 2006, Congress passed the Combat Methamphetamine Epidemic Act, which aimed at 
reducing the availability of pseudoephedrine and ephedrine as starting materials for illegal meth 
production.14,21 As part of the act, pharmacies are required to record the number of store bought 
medicine packages that contained either ephedrine, pseudoephedrine, or phenylpropanolamine, 
for up to two years.17 Later, many state pharmacies removed these packages from the shelves and 
placed them behind the counter. To this day, many states require a driver’s license and a signature 
for the purchase of these products. 
 Despite the growing limitations placed on the availability of pseudoephedrine and 
ephedrine, meth cooks adapted to the situation and began to produce meth using the One-Pot 
method. This method, a modified version of the Birch reduction method, uses crushed 
pseudoephedrine tablets as the starting material with lithium metal and ammonia to result in d-
meth.22 The materials needed for the reaction process can be easily obtained from any local store 
and placed into small, carriable containers. Meth cooks then only need to continually shake and 
release the built-up gases inside the container to yield d-meth.  
2.4. Enantiomers 
 Methamphetamine and amphetamine enantiomers are chiral compounds, in other words, 
compounds that are non-superimposable mirror images, as seen in Figures 1-2.4 These chiral 
chemical compounds have two optical isomers, called enantiomers: d(+)-dextrorotatory and l(-)-
levorotatory.4-5,11,16,23 Enantiomers are compounds that have the same physical and chemical 
properties, but the only difference between them is the direction the drug or chemical rotates in 
polarized plane light, as seen in Figures 1-2.4 Dextrorotatory compounds rotate polarized light to 
the right and are “right-handed.”7 Levorotatory compounds, on the other hand, rotate polarized 
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light to the left and are “left-handed.”7  Enantiomers are chemical compounds that are mirror 
images of each other and can exist independently but also equally as racemates.  
2.4.1. Pharmacology 
 When meth and amphetamine are used, these drugs can cause increased alertness, 
euphoria, and a general sense of well-being in the user by increasing the norepinephrine and 
dopamine levels in the central nervous system (CNS).7,16,24 When either drug is smoked or 
injected, the effects will be almost instantaneous.7 Meth and amphetamine use can also produce 
the “fight-or-flight” response associated with the peripheral nervous system.7,16 The fight-or-flight 
response is characterized by an increased heart rate, blood pressure, and glucose blood levels.16 
When either drug is taken in high doses, serious health complications can develop like irregular 
heartbeat, skin tremors, or even heart attacks.16 The enantiomers of either drug will affect the 
body in separate ways depending on the form. The d-isomers are more physiologically active in 
the CNS, which means that are more likely to be abused.7,23 The d-form of meth is referred as 
street meth because it is five times more reactive than the l-form.4 This form of meth is the active 
ingredient in decongestant medicines like Vicks® VapoInhaler™ because it is more 
physiologically active in the peripheral nervous system. 
2.5. Analytical Methods 
The separation and quantification of the chiral enantiomers of meth and amphetamine is not a 
new topic in forensic science. As technology advances and becomes more efficient, more specific 
analytical techniques for the separation and quantification of drug enantiomers will emerge. Most 
drug screening methods that are employed in forensic and clinical toxicology labs today are 
geared towards identifying the more physiologically active d-enantiomer for either drug.23  
 These screening methods will not identify the difference between either the d- or l-meth 
and/or amphetamine enantiomers, but only if an analyzed sample screened positive for the 
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presence of meth or amphetamine.7,11 These positively-screened results need to be confirmed by a 
second analytical method. Two confirmatory techniques that are commonly used for the chiral 
separation of enantiomers, gas chromatography and liquid chromatography, will be discussed. A 
variety of detectors can be used with either technique, but this paper will focus on mass 
spectrometry (MS) as the detector of choice. There are three common methods that are employed 
for the enantiomeric separation of chiral enantiomers; only the two most advantageous methods 
for our clinical lab will be discussed. 
2.5.1. Gas chromatography 
 Gas chromatography, or GC, combined with a mass spectrometer (MS) detector, has been 
the instrument of choice for the separation of meth and amphetamine enantiomers.4,7,11 However, 
there is a distinct disadvantage to using this technique. During analysis, drug samples are exposed 
to extreme heat to volatilize them for analysis. Many drugs and substances become unstable at 
elevated temperatures. GC-MS is typically performed using a chiral derivatization reagent, which 
is added to a sample prior to column analysis, to create diastereomers.6 These reagents are special 
chemicals that are added to a sample to make them more stable for analysis. However, chiral 
reagents can affect the percentages of meth and amphetamine enantiomers in samples of 
suspected abusers. This technique can also produce relatively high error rates and cause 
racemization of enantiomers to occur.6 
2.5.2. Liquid chromatography 
 Liquid chromatography, or LC, combined with two MS detectors (LC-MS/MS), is 
becoming the staple technique in forensic and clinical toxicology labs due to its ability to detect 
very low levels of drugs and substances in samples. LC methods often require less sample 
preparation and can be used with or without a chiral derivatization reagent. When compared to 
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GC-MS, LC-MS/MS can lead to more accurate results because racemization of enantiomers is not 
as likely to occur since pre-column derivatization is not used.6 
 With LC-MS/MS, there are three common methods that are used for the enantiomeric 
separation of meth and amphetamine. The first method involves the use of a chiral derivatization 
reagent to form diastereomers for the analysis of enantiomers on an achiral column.4,25 The 
second method a forensic and clinical toxicology lab can consider is with a chiral column. 4,25 The 
third method for the enantiomeric separation of meth and amphetamine enantiomers is the 
addition of a chiral selector as an additive in a mobile phase. 4,25 
 A chiral column will eliminate the need for derivatization of a sample prior to injection. 
The sample will undergo preparation and then it will be injected directly onto the column for 
analysis. The enantiomers, when introduced to the column, will react differently with the internal 
environment to allow for separation of enantiomers to be achieved.5 There are many published 
LC methods using chiral columns to separate meth and amphetamine enantiomers.5-6,11-14 Several 
types of commercial chiral column stationary phases are available, including cyclodextrin, chiral 
ligand exchange, and macrocyclic glycopeptides.26-27 Vancomycin is an example of a macrocyclic 
glycopeptide chiral stationary phase, often seen in Astec ChirobioticTM columns. Vancomycin is a 
chiral stationary phase that consists of a non-sugar portion of various fused macrocyclic rings 
surrounded by connected portions of carbohydrate molecule groups, bounded to fused silica.27 
The Astec Chirobiotic™ column from Sigma-Aldrich has effectively separated and quantified 
both meth and amphetamine enantiomers in common biological specimens of forensic interest, 
including urine, blood, and oral fluid.5,7,12-13,15 
 A major disadvantage of using chiral columns is that they are often very expensive. 
Forensic and clinical toxicology labs, which have strict budgets or not much in the way of 
14 
 
available funding, may find themselves unable to adopt of a method with such an expensive 
component. 
 The expense of chiral columns means that many forensic and clinical toxicology labs 
look for more cost-effective separation methods. One such method is the use of derivatization 
with a chiral derivatization reagent, which is much less expensive. Studies show that reagents like 
1-fluoro-2,4-dinitrophenyl-5-L-aniline amide (Marfey’s reagent) and 9-fluorenylmethly 
chloroformate-L-proline (FMOC-L-Pro) are effective chiral derivatization reagents for the 
separation of methamphetamine and amphetamine enantiomers.4,7,14-15 The addition of the chiral 
derivatization reagent to an enantiomer will form diastereomers that can be analyzed using 
standard achiral chromatography, including normal and reversed phase means. For normal phase 
HPLC, the stationary phase is made up of polar packing materials, like silica. By increasing the 
strength of the nonpolar mobile phase, the least polar analytes will elute off the column first, 
followed by the more polar analytes. Reversed phase HPLC works in the exact opposite manner; 
the stationary phase is made up of nonpolar packing materials, like C18 or C8 chains. By 
increasing the strength of the polar mobile phase, the least nonpolar analytes elute off the column 
first, followed by the more nonpolar analytes.  
2.6. Extraction Methods 
 Two extraction methods that are commonly employed in forensic and clinical toxicology 
labs for chiral separation of d- and l-enantiomers of meth and amphetamine include liquid-liquid 
extraction and solid phase extraction.6-7,11-12,14-15,28-34 
2.6.1. Liquid-Liquid Extraction Process 
 Liquid-liquid extraction, or LLE, is an analytical extraction process where an immiscible 
extraction solvent is added to a sample and the aqueous phase (usually water) and the organic 
phase are mixed together by shaking to allow for the separation of analytes to occur between the 
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two phases. The phase that contains the analytes of interest is removed, the extraction solvent is 
then dried down, resuspended in a polar organic solvent, and injected onto the instrument.  
2.6.2. Solid Phase Extraction Process 
 Solid phase extraction, or SPE, is an alternative extraction process to the LLE process 
described above. By using a cartridge column device that is filled with solid particle packing 
material (stationary phases), liquid samples can be chemically divided into analyzable parts 
through various elution steps.35-36 Figure 3 shows an example of the overall SPE process 
described.36 
 
Figure 3: SPE process36 
2.7. Conclusion 
 Methamphetamine and amphetamine are CNS stimulant drugs that have a long history of 
abuse. With increasing rules and regulations placed on the common starting materials used in the 
illegal production of meth and amphetamine, there have been a variety of methods developed. 
These methods include P2P, Red Phosphorous, Birch reduction, and the One-Pot methods. The 
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P2P method will result in a racemic mixture of both d- and l-enantiomers of meth. The Red 
Phosphorous and Birch reduction methods can sometimes result in d-amphetamine, depending on 
the starting material used. The Red Phosphorous, Birch reduction, and One-Pot methods will 
result in d-enantiomer of meth.  
 The separation and quantification of meth and amphetamine enantiomers is not a new 
problem in forensic and clinical toxicology labs.  Many labs will employ screening methods that 
cannot tell the difference between either enantiomer; only if an analyzed sample screens positive 
for the presence of meth and/or amphetamine. These positive samples should be sent to an off-site 
lab for the separation analysis. The process of sending the positive samples to another lab for the 
separation analysis can get expensive in the long run. While GC and LC are common techniques 
used for the analysis of drug enantiomers, LC is becoming more popular. Many LC studies use an 
expensive chiral column that can eat a lab’s bottom-line profits. 
 The purpose of this research was to develop a simple and cost-effective chiral separation 
method to separate d- and l-meth and amphetamine in urine samples using LC-MS/MS. Three 
separation methods were developed: two using an Astec Chirobiotic chiral column, and one using 
an achiral column to determine which chiral method was more effective at enantiomeric 
separation for either drug. Through this research, the Oklahoma State University Clinical 
Laboratory Services will have the ability to conduct the separation analyses of meth and 
amphetamine enantiomers in-house. 
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CHAPTER III 
 
 
III. METHODOLOGY 
 
3.1. Overview 
 The purpose of this project was to develop and compare a cost-effective a chiral 
separation method that separated the d- and l-enantiomers of methamphetamine (meth), and its 
primary metabolite, amphetamine (amp), via LC-MS/MS. This chapter outlines three separation 
methods were developed: two using a chiral column and one using Marfey’s reagent for pre-
column derivatization. The separation power of each method was evaluated to determine which 
method was more effective at the separation of the d- and l-enantiomers of both meth and amp in 
urine. 
 Topics discussed within this chapter include: chemicals and equipment used for each 
separation method, instrumentation, and the LC-MS/MS separation parameters determined for 
each method. The sample extraction processes for the chiral column and the pre-column 
derivatization methods, along with the derivatization process with Marfey’s reagent, are also 
discussed. Other topics include the data analysis for each method and future validation. 
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3.2. Chemicals and Equipment 
3.2.1. Materials 
 d-amphetamine, l-amphetamine, ±-amphetamine, d-methamphetamine, l-
methamphetamine, ±-methamphetamine (1 mg/mL), and internal standards ± d5-
methamphetamine and ± d6-amphetamine (1 mg/mL) were purchased from Cerilliant (Round 
Rock, TX). ACS-grade ammonium hydroxide was purchased from BDH (West Chester, PA). 
ACS-grade hydrochloric acid was purchased from Fisher Scientific (Waltham, MA). ACS-grade 
methanol was purchased from J.T. Baker (Center Valley, PA). ACS-grade ethyl acetate was 
purchased from Honeywell (Muskegon, MI). Ammonium formate was purchased from Alfa 
Aesar (Ward Hill, MA). ACS-grade sodium bicarbonate was purchased from J.T. Baker 
(Phillipsburg, NJ). Marfey’s reagent was purchased from TCI (Portland, OR). ACS-grade 
acetone, glacial acetic acid, and formic acid were purchased from EMD (Billerica, MA).  
Deionized pure water was produced on-site with a Thermo Scientific Barnstead Nanopure water 
purification system from ThermoFisher Scientific (Asheville, NC). 
3.2.2. Reagents and Solutions 
 A variety of solutions were needed throughout each separation method. For the chiral 
column solid phase extraction (SPE) and dilute and shoot (D & S) extraction methods, a solution 
of 0.1 % glacial acetic acid + 0.02 % ammonium hydroxide in methanol was prepared for the 
mobile phase solution. A hydrolysis solution was prepared for the D & S extraction method, 
containing internal standards, 0.1 M pH 4.0 acetate buffer, and water. A sample diluent solution 
of 95:5 water/methanol was prepared weekly. 
 For the pre-column derivatization reagent SPE separation method, a gradient elution was 
used with a solution of 2mM ammonium formate + 0.1 % formic acid mobile phase solution 
prepared in both methanol and water. Additional solutions included 0.1 % Marfey’s reagent in 
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acetone and 1.0 M methanolic hydrochloric acid in water. The Marfey’s reagent was stored at 
4°C in an amber bottle for up to one month.7 
 For both the SPE separation methods for the chiral column and the pre-column 
derivatization method, an elution solution of 98:2 ethyl acetate/ammonium hydroxide was 
prepared fresh daily and stored at room temperature. A 1.0 M sodium bicarbonate in water 
solution was prepared. A 500 ng/mL working solution of each analyte, one with both meth 
enantiomers, and one with both amphetamine enantiomers, listed in the materials section, was 
made up separately in urine. 
3.2.3. Instrumentation 
 All samples were analyzed with a Shimadzu HPLC system from Shimadzu Corporation 
(Kyoto, Japan). The HPLC system consists of a system controller, CBM-20A, a solvent delivery 
unit, LC-20AD, an auto-sampler, SIL-20AC, and a column oven, CTO-20AC.  
 The Shimadzu HPLC system is attached to an Applied Biosystems 4000 Q-Trap LC-
MS.MS System from AB Sciex (Foster City, CA). The mass spectrometer is equipped with a 
Turbo VTM electrospray ionization source, a Harvard Apparatus syringe pump (Holliston, MA) 
and a Genius2 3020 Nitrogen generator from Peak Scientific (Billerica, MA). Analyst 1.6.2 
Software was used to control the instrument, sample data collection, and analysis. 
3.3. Urine Samples 
 Five anonymized urine samples were provided by OSU-CLS in Tulsa, Oklahoma for 
testing. Four samples were negatively confirmed for meth, while one sample was positive for 
meth. 
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3.4. Chiral Separation Method Development 
3.4.1. Chiral Column Method 
3.4.1.1. Sample Extraction Methods 
3.4.1.1.1 Dilute and Shoot 
 The dilute and shoot (D & S) method is an extraction method, where a sample is diluted 
prior to injection onto an instrument, that is often employed in forensic and clinical toxicology 
labs. Prior to any sample workup, an internal standard solution of 1 μg/mL internal standard, 0.1 
M pH 4.0 acetate buffer, and water was made, and then centrifuged for 10 minutes at 13,000 rpm. 
To a 2 mL Eppendorf tube, 50 μL of the 500 ng/mL working urine solution sample + 50 μL 
internal standard solution were added. The samples were vortexed for 10 seconds before the 
addition of 150 μL of a 95:5 water/methanol. The samples were vortexed for 10 seconds, then 
centrifuged for 10 minutes at 13,000 rpm. Next, 200 μL of the supernatant was transferred to an 
injection vial prior to instrumental analysis.  
3.4.1.1.2 Solid Phase Extraction 
 The solid-phase extraction (SPE) method was adapted from SPEware Corporation.37 
Trace-N SPE columns from SPEware were used. To wash the SPE columns to prepare them for 
the addition of the sample solution, 2 mL ethyl acetate was pulled through the columns under a 
vacuum into waste at a flow of 1.0 mL/min. The process was repeated with 2 mL methanol, then 
with 1 mL water. Next, 50 µL of the 500 ng/mL working urine solution was added to its labeled 
column and pulled through with a vacuum at a flow rate of 1.0 mL/min.  
 The columns were washed again with 2 mL 1.0 M sodium bicarbonate, then with 2 mL 
water. Next, the columns were dried for 6 minutes at 80 psi. Next, the d/l-meth and amp 
enantiomers were eluted from the columns with 2 mL 98:2 ethyl acetate/ammonium hydroxide 
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elution solution. The elution tubes were evaporated to dryness for 30 minutes at 45 °C under a 
stream of nitrogen. Next, the samples were resuspended in 200 μL 0.1 % glacial acetic acid + 
0.02 % ammonium hydroxide in methanol. The samples were vortexed for 10 seconds, and then 
180 μL of the solution was transferred to an injection for instrumental analysis.  
3.4.1.2. LC-MS/MS Parameters 
 The LC-MS/MS conditions were optimized to achieve baseline separation of d/l-meth 
and d/l-amp using an Astec CHIROBIOTIC V2 Chiral column (25 cm x 2.1 mm, 5 μm) under 
isocratic conditions with 100 % 0.1 % glacial acetic acid + 0.02 % ammonium hydroxide in 
methanol for 13 minutes. The oven temperature was set to 25 °C with a flow rate of 0.25 mL/min 
and an injection volume of 2 μL. Mass spectrometry data was acquired using ESI positive mode. 
The gas temperature was set to 350 °C and the capillary voltage set to 1000 V. Multiple reaction 
monitoring mode (MRM) was chosen to allow multiple user defined ion fragments for each 
enantiomer to be monitored. MRM transitions and MS/MS details can be seen in Table 1. The 
retention times for each extraction method for each analyte are listed in Table 2. 
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Table 1: MRM values & MS/MS details for the chiral column method. The precursor and 
product ions m/z (Q1 & Q3), declustering potential (DP), collision energy (CE), and collision exit 
potential (CXP) values for d- and l-meth and amp enantiomers are listed.  
Analyte Q1 (Da) Q3 (Da) DP 
(Volts) 
CE 
(Volts) 
CXP 
(Volts) 
Methamphetamine 150.10 91.00 56 25 14 
Methamphetamine 150.10 119.00 56 15 4 
Methamphetamine-D5 155.00 91.10 60 20 4 
Amphetamine 136.20 91.00 36 25 14 
Amphetamine 136.20 119.00 36 13 18 
Amphetamine-D6 142.10 125.10 41 13 6 
l-Amphetamine 136.10 91.00 21 23 14 
l-Amphetamine 136.10 119.00 36 10 18 
d-Amphetamine 136.15 91.11 1 21 14 
d-Amphetamine 136.15 119.00 36 10 18 
l-Methamphetamine 149.667 91.20 1 19 10 
l-Methamphetamine 149.667 119.10 1 15 18 
d-Methamphetamine 150.094 90.90 101 29 14 
d-Methamphetamine 150.094 118.90 101 15 18 
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Table 2: Retention times and MS/MS details for the chiral column method extraction 
methods. The precursor and product ions m/z (Q1 & Q3) and retention times (RT) for d- and l-
meth and amp enantiomers are listed. Since two peaks were observed for all analytes, the 
averaged retention times between each observed peak are listed. 
Analyte Q1 (Da) Q3 (Da) SPE RT (min) D & S RT (min) 
Methamphetamine 150.10 91.00, 119 9.25 10.23 
Methamphetamine-D5 155.00 91.10 - 8.61 
Amphetamine 136.20 91.00, 119 7.97 7.65 
Amphetamine-D6 142.10 125.10 - 8.61 
l-Amphetamine 136.10 91, 119 7.95 7.64 
d-Amphetamine 136.15 91.11, 119 9.94 7.63 
l-Methamphetamine 149.667 91.20, 119.10 9.70 8.57 
d-Methamphetamine 150.094 90.90, 118.90 9.83 8.46 
 
3.4.2. Pre-Column Derivatization Reagent Method 
3.4.2.1. Sample Extraction 
 The solid-phase extraction (SPE) method was adapted from SPEware Corporation, as 
described in section 3.4.1.1.2.37 The derivatization method was adapted from Mitchell7 and 
Newmeyer et al.15 After evaporation under a stream of nitrogen for 30 minutes at 45°C, the 
samples were resuspended in 100 μL water + 20 μL of 1.0 M sodium bicarbonate, and then 
vortexed for 10 seconds. Next, 100 μL of 0.1 % Marfey’s reagent in acetone was added, and then 
the tubes were vortexed for 10 seconds to mix the contents together. 
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Figure 4:  Marfey’s reagent in acetone is bright yellow 
 Then, the samples were heated at 45°C for 1 hour. After 60 minutes, the samples are 
cooled to room temperature before the addition of 40 μL 1.0 M hydrochloric acid, and then 
vortexed for 5 seconds.  
 
  
 
D-Meth L-Meth D-Amp L-Amp 
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Figure 5. (Left) The heating process will cause the samples to change from yellow to red. The 
samples are labeled as: d-meth (A), l-meth (B), d-amp (C), and l-amp (D). (Right) The addition of 
HCl will create the yellow bottom layer 
 Then, the samples are taken to dryness under a stream of nitrogen for 2 hours at 45°C. 
Next, the samples are resuspended in 200 μL of 2 mM ammonium formate + 0.1 % formic acid in 
methanol. Next, the samples were vortexed for 10 seconds before centrifuging for 5 minutes at 
2800 rpm. Then, 180 μL of the supernatant was transferred to an LC injection vial for 
instrumental analysis.  
3.4.2.2. LC-MS/MS Parameters 
 The LC-MS/MS conditions were optimized in the hopes of achieving baseline separation 
of d/l-meth and d/l-amp using an Restek Raptor Biphenyl achiral column (50 x 2.1 mm, 2.7 μm) 
with a guard column under binary flow conditions with 7.2 % mobile phase B (2 mM ammonium 
formate + 0.1 % formic acid in methanol) and 92.8 % mobile phase A (2 mM ammonium formate 
+ 0.1 % formic acid in water) for 8 minutes. A time program was used to vary the pump B % 
concentration. For 3.50 minutes, the pump B %concentration was held at 7.2 %, then increased to 
35 % at 3.51 minutes. The pump B % concentration was then held at 35 % until 4.51 minutes, 
where it decreased back to 7.2 %. The total run time was 12 minutes. The oven temperature was 
A B C 
D 
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set to 30 °C with a total flow rate of 0.70 mL/min with an injection volume of 2 μL. Mass 
spectrometry data was acquired using ESI positive mode. MRM transitions and MS/MS details 
can be seen in Table 2. Only retention times for the un-derivatized meth and amp analytes are 
noted below, because the derivatives of each enantiomer were not observed at this time.  
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Table 3: MRM values & MS/MS details for the pre-column derivatization method. The same 
descriptions listed for Table 1 are also used. 
Analyte Q1 (Da) Q3 (Da) DP (Volts) CE (Volts) CXP (Volts) RT (min) 
Derivatized d-Amphetamine 386.10 136.10 46 19 6 - 
Derivatized d-Amphetamine 386.10 91.10 46 19 6 - 
Derivatized d-Methamphetamine 400.20 150.10 56 17 12 - 
Derivatized d-Methamphetamine 400.20 91.10 56 69 24 - 
Derivatized l-Amphetamine 386.10 136.10 46 19 6 - 
Derivatized l-Amphetamine 386.10 91.10 46 19 6 - 
Derivatized l-Methamphetamine 400.20 150.10 56 17 12 - 
Derivatized l-Methamphetamine 400.20 91.10 56 69 24 - 
Methamphetamine 150.10 91.00 56 25 14 4.23 
Methamphetamine 150.10 119.00 56 15 4 4.23 
Amphetamine 136.20 119.00 36 13 18 2.71 
Amphetamine 136.20 91.00 36 25 14 2.70 
Methamphetamine-D5 155.00 91.10 60 20 4 5.15 
Amphetamine-D6 142.10 125.10 41 13 6 4.59 
 
3.5. Method Validation 
 Since for this project, were only interested in the detecting the presence of d or l meth 
and/or amp, a quantitative multi-point calibration curve was not used at this time. Method 
validation studies according to SWGTOX guidelines will be conducted by the OSU-CLS prior to 
clinical incorporation of this method.38 Only the efficiency of the chiral column separation 
methods was investigated. 
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3.6. Data Analysis  
 Data were analyzed using the Analyst 1.6.2 software to determine the retention times of 
the peaks and their widths for the D & S and SPE separation methods for the chiral column. 
Using Microsoft Excel, the average resolution or R-values, for each day of experiments was 
determined for the meth and amp mixture samples. The average R-values were calculated using 
the Analyst software generated values and were compared to the values determined by hand. 
GraphPad Prism software (San Diego, CA) was used to calculate the p-values and the 95% 
confidence intervals between the chiral column extraction methods for each drug to determine 
which extraction technique was more efficient at the enantiomeric separation.38 
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CHAPTER IV 
 
 
IV. RESULTS 
 
4.1. Presentation of Results 
4.1.1. Chiral Column Results 
 Baseline separation was achieved for both the SPE and D & S extraction methods 
developed for the chiral column for amphetamine only. Baseline separation was achieved for 
methamphetamine for the SPE method, but not for the D & S. Figure 6 shows the baseline 
separation of d- and l-enantiomers of both meth and amphetamine in a spiked 500 ng/mL urine 
sample extracted with the SPE method for one sample run. The d-enantiomer always eluted off 
the column first, followed soon after by the l-enantiomer for both methamphetamine and 
amphetamine for both extraction methods. The average retention times for the methamphetamine 
and amphetamine enantiomers are listed in Table 2 for the chiral column extraction methods.
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Figure 6: Baseline separation of d- and l-amphetamine and methamphetamine enantiomers with 
SPE extraction method 
 Figure 7 is an example of the spiked 500 ng/mL urine sample extracted with the D & S 
extraction method showing baseline separation of d- and l-enantiomers of amphetamine. Figure 8 
is the extracted urine sample described for Figure 7, showing separation of d- and l-enantiomers 
of methamphetamine.  
D-Amp 
RT = 7.56 
L-Amp 
RT = 8.58 
D-Meth 
RT = 9.39 L-Meth 
RT = 10.37 
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Figure 7: Separation of d- and l-amphetamine enantiomers with D & S extraction method 
 
Figure 8: Baseline separation of d- and l-methamphetamine with D & S extraction method 
L-Amp 
RT = 7.85 D-Amp 
RT = 7.10 
D-Meth 
RT = 8.36 L-Meth 
RT = 8.82 
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 The Analyst 1.6.2 software was used to determine the retention times of the observed 
peaks and their widths for both extraction methods. The average R-values were calculated using 
the resolution equation,39 
𝑅 =
(𝑡𝑟𝑏 − 𝑡𝑟𝑎)
(
1
2)(𝑊𝑏𝑎 +𝑊𝑏𝑏)
 
 Where R is the resolution, tr is the peak retention time; tra for peak a, trb for peak b, and wb 
is the average width of the peak at the base; wba for peak a, wbb for peak b. The average R-values 
were calculated using the Analyst calculated values and were compared to the values determined 
by hand. This data is presented in Tables 4 and 5. Table 4 are the SPE extraction R-values using 
the Analyst computer generated values (CPU) and the hand-generated values (Hand). Table 5 are 
the D & S extraction R-values using the Analyst generated values and the hand-generated values. 
A single sample was extracted once for each extraction method and run over the course of 3 days. 
The average R-values for each drug for an extraction method were calculated and reported.  
 
Table 4: Chiral Column - SPE Extraction R-values. 
Days CPU Meth Mix CPU Amp Mix Hand Meth Mix Hand Amp Mix 
Day 1 0.87 1.15 0.94 1.21 
Day 2 0.90 0.94 0.92 0.99 
Day 3 0.87 0.84 0.93 0.83 
Average 0.88 0.98 0.93 1.01 
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Table 5: Chiral Column - D & S Extraction R-values. 
Days CPU Meth Mix CPU Amp Mix Hand Meth Mix Hand Amp Mix 
Day 1 0.78 0.72 0.88 0.90 
Day 2 0.73 0.75 0.77 0.75 
Day 3 0.67 0.80 0.70 0.96 
Average 0.72 0.76 0.79 0.83 
 
 A total of 5 unknown extracted urine samples provided from OSU-CLS, labeled A-E, 
were analyzed over the period of 2 days. The samples fell into two broad categories: positive for 
methamphetamine or negative for methamphetamine. For all the analyzed samples, the presence 
of amphetamine was determined. One sample was positive for methamphetamine, specifically d-
methamphetamine and d-amphetamine, while the other four samples were negative for meth and 
amphetamine. These unknown samples were compared to the retention time of the 1 µg/mL 
Cerilliant standards listed in Table 6.  
 
Table 6: Cerilliant standards (1 µg/mL in methanol) retention times 
Cerilliant Standards  Retention Times (min) 
d-Amphetamine 7.31 
l-Amphetamine 8.27 
d-Methamphetamine 9.04 
l-Methamphetamine 9.97 
±-Amphetamine 7.57, 8.58 
±-Methamphetamine 9.38, 10.37 
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 The retention times for each standard was obtained with the optimized LC-MS/MS chiral 
column parameters listed in the methodology chapter. Figure 9 shows the chromatogram for 
Unknown E that was negative for meth and amphetamine.  
 
Figure 9: Unknown sample E negative for amphetamine and methamphetamine 
 Figure 10 shows the chromatogram for Unknown D that was positive for 
methamphetamine. When the observed peak was compared to the retention times standards in 
Table 8, it was determined that this unknown sample was positive for d-methamphetamine, at 
8.91 minutes. There is a small peak observed around 7.33 minutes that was determined to be d-
amphetamine. 
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Figure 10: Unknown sample D that was positive for d-meth and d-amp 
4.1.2. Pre-Column Derivatization Results 
 There was no significant difference between the 500 ng/mL derivatized and the un-
derivatized urine samples, when using the conditions listed in the methodology chapter, using a 
mobile phase of 2 mM ammonium formate + 0.1 % formic acid in methanol (mobile phase B) or 
water (mobile phase A). Figure 11 is the un-derivatized 500 ng/mL urine sample, that shows the 
ion ratios of d/l-amphetamine and d/l-methamphetamine, labeled A-D. Figure 12 is of the 
derivatized 500 ng/mL urine sample, with the same letter labels as Figure 11. 
 
D-Meth 
RT = 8.91 
D-Amp 
RT = 7.33 
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Figure 11: Underivatized 500 ng/mL urine sample, showing relative ion ratios. A: Derivatized d-
amp. B: Derivatized l-amp. C: Derivatized d-meth. D: Derivatized l-meth 
 
Figure 12: Derivatized 500 ng/mL urine sample showing relative ion ratios. A: Derivatized d-
amp. B: Derivatized l-amp. C: Derivatized d-meth. D: Derivatized l-meth
A B 
C D 
A B 
C D 
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CHAPTER V 
 
 
V. DISCUSSION 
 
5.1 Discussion 
5.1.1. Chiral Column Separation Method Discussion 
 The purpose of this research was to develop a cost-effective chiral separation method 
using an Astec Chirobiotic chiral column, to separate d- and l-meth and amphetamine in urine 
samples using LC-MS/MS. A separation method using Marfey’s chiral derivatization reagent was 
also attempted for an achiral column. The research hypothesized that the SPE extraction method 
was going to be more efficient at the enantiomer separation for both drugs when compared to the 
D & S method for the chiral column. Baseline separation for both chiral column extraction 
methods would also be achieved. The research also hypothesized that baseline separation of the 
derivatized enantiomers for both meth and amphetamine would be achieved with pre-column 
derivatization with Marfey’s chiral derivatization reagent.  
 The overall results were mixed, in regards with the stated hypotheses. The p-value for the 
ANOVA comparison test of the average R-values from tables 4 and 5 for meth is p = 0.0067, F = 
8.693. Therefore, when α = 0.05, p < α, there is sufficient evidence to partially disprove the 
hypothesis that the SPE extraction method would be more efficient at the enantiomeric separation 
of meth when compared to the D & S extraction method. 
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 There is a statistical difference observed between the average R-values calculated using 
either resolution calculation method between the two chiral column extraction methods for meth. 
 The p-value for the ANOVA comparison test for amphetamine is p = 0.1377, F = 2.456. 
When α = 0.05, p > α, there is insufficient evidence to reject the hypothesis that the SPE 
extraction method would be more efficient at the separation of amp enantiomers compared to the 
D & S extraction method. There is no statistical difference observed between either resolution 
calculation for amp when using either extraction method.  
 A Tukey’s multiple comparisons test was conducted to investigate where the differences 
are between the experimental conditions of the average R-values between the SPE and D & S 
extraction methods obtained using either the Analyst computer generated values or by hand. This 
was done to determine if there is a significant difference between using the Analyst software 
generated R-values and the hand-calculated R-values for either drug between the two extraction 
methods used for the chiral column. Table 7 shows the 95% confidence interval values and the 
multiple comparisons means that were generated using GraphPad Prism software for meth. Table 
8 lists the p-values for the pairwise comparisons when α = 0.05 for meth. A result is significant if 
p ≤ α.  
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Table 7: Meth Multiple comparisons 95% confidence intervals (CI). CPU are the Analyst 
software R-values, while Hand are the R-values using the SPE and D & S average R-values from 
tables 4 and 5.  
Method Lower 95% CI Upper 95% CI 
CPU SPEB 0.84 0.92 
Hand SPEA,C 0.91 0.95 
CPU D & SB,C 0.59 0.86 
Hand D & SA 0.56 1.01 
 
Table 8: Meth Pairwise comparisons p-value & 95% confidence intervals. CPU are the 
Analyst software R-values, while Hand are the R-values using the SPE and D & S average R-
values from tables 4 and 5. A result is significant if p ≤ α, when α = 0.05. 
Method Pair Adjusted p-value 95% CI Significant? 
CPU D & S vs Hand D & S 0.5960 -0.198 to 0.0845 No 
CPU D & S vs CPU SPEB 0.0340 -0.295 to -0.0121 Yes 
CPU D & S vs Hand SPEC 0.0075 -0.345 to -0.0621 Yes 
Hand D & S vs CPU SPE 0.2049 -0.238 to 0.0445 No 
Hand D & S vs Hand SPEA 0.0420 -0.288 to -0.00546 Yes 
CPU SPE vs Hand SPE 0.6806 -0.191 to 0.0912 No 
   
 There is a statistical mean difference observed between the groups listed in Tables 7-8 
that have the same letter notation, when α = 0.05, because these intervals do not contain 0. There 
is a statistical group mean difference between using the Analyst generated R-values compared to 
the by hand R-values for meth. Table 9 lists the 95% confidence interval and multiple comparison 
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mean values that were generated using GraphPad Prism software for amphetamine. Table 10 lists 
the p-values for the pairwise comparisons when α = 0.05 for amphetamine. A result is significant 
if p ≤ α.  
 
Table 9: Multiple comparisons 95% confidence interval (CI) values for amphetamine. The 
same descriptions used in Table 7 were used. 
Method Lower 95% CI Upper 95% CI 
CPU SPE 0.58 1.37 
Hand SPE 0.54 1.49 
CPU D & S 0.66 0.86 
Hand D & S 0.64 1.03 
 
Table 10: Amphetamine Pairwise comparisons p-value & 95% confidence intervals. The 
same descriptions used in Table 8 were used. 
Method Pair Adjusted p-value 95% CI Significant? 
CPU D & S vs Hand D & S 0.8761 -0.424 to 0.264 No 
CPU D & S vs CPU SPE 0.2474 -0.564 to 0.124 No 
CPU D & S vs Hand SPE 0.1630 -0.597 to 0.0903 No 
Hand D & S vs CPU SPE 0.5852 -0.484 to 0.204 No 
Hand D & S vs Hand SPE 0.4226 -0.517 to 0.170 No 
CPU SPE vs Hand SPE 0.9888 -0.377 to 0.310 No 
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 The 95% confidence intervals for each separation methods for amphetamine overlap each 
other, leading to the assumption there is no significant difference between using the Analyst 
software generated R-values when compared to the by hand R-values for amphetamine. From the 
pairwise comparison table above, no method pair that is listed is significant because p ≥ α, when 
α = 0.05.  
5.1.2. Pre-Column Derivatization Method Discussion 
 At this point in time, the extracted samples were not being derivatized because the ion 
ratios of the derivatized samples for both meth and amphetamine were like the un-derivatized 
sample ion ratios for either drug. With the inability to derivatize the extracted samples, it was not 
possible to achieve baseline separation of the enantiomers for with this chiral separation method. 
Tests were conducted to determine if the urine samples were eluting off the Trace N SPE columns 
or not. By analyzing the extracted un-derivatized samples and comparing the chromatograms with 
expected peak retention times gathered from previous testing, it was noted that d-meth and 
amphetamine were being detected by the instrument, as expected, as shown in Figures 13 and 14. 
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Figure 13: Non-derivatized d-amphetamine 
 
Figure 14: Non-derivatized d-methamphetamine 
 
D-Amp 
RT = 1.49 
D-Meth 
RT = 2.77 
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 It could be that the derivatization process that was used was not the correct method for a 
Restek Raptor Biphenyl achiral column, which is why the derivatized samples were unable to be 
detected due to the chiral derivatization reagent is not binding to the stationary phase of the 
column very tightly. The small ion ratios observed for the derivatized samples could also be due 
to a degraded column, therefore the derivatized analytes are not sticking to the column very 
tightly to allow for sufficient detection by the instrument. 
5.2. Validation 
 Since the five anonymized urine samples were previously tested for the presence of meth 
and amphetamine, a multi-point calibration curve was not used at this time. A water sample was 
injected between each urine sample to assess potential carryover. No added meth or amphetamine 
was observed in each injected urine or water sample, indicating that no carryover between 
samples occurred. Before using either extraction scheme for the chiral column separation method, 
a complete validation study according to SWGTOX guidelines will need to be conducted.38 A 
pre-column derivatization method using Marfey’s chiral derivatization reagent in urine will need 
to be developed and validated at a later time so that a comparison study can be conducted 
between the chiral column and an achiral column pre-column derivatization method to determine 
which method is more efficient at the enantiomeric separation of meth and amphetamine.  
5.3. Study Benefits 
 One of the major benefits of the study is that it is possible to qualitatively separate the d- 
and l-enantiomers of meth and amphetamine in urine in-house, rather than sending these positive 
samples out to an off-site for the separation testing to be conducted.  The SPE and D & S 
separation methods are relatively simple and did not require any specialized chemicals or 
reagents. While this study focused on a clinical application, the chiral column separation methods 
can be easily adapted for antemortem settings.  
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 Methamphetamine use in the United States is on the rise. This research provides an 
example of a clinical application of the qualitative detection and separation of d- and l-
enantiomers of meth and amphetamine in positively confirmed meth and/or amphetamine urine 
samples. The analysis of the type of meth and amphetamine in a sample can potentially provide 
information about the type of production method used, the identity of the starting materials used 
for a specific method, and if an individual is compliant with a prescribed drug therapy or not.  
5.4. Limitations 
 While the positive results can imply the type of production method used to produce meth 
and/or amphetamine, it is not possible to know exactly where an individual acquired the drug. It 
is possible that the individual in question is legally prescribed Vicks VapoInhalaerTM to clear a 
stuffy nose. 
 Another limitation was that the development of a pre-column derivatization method with 
Marfey’s reagent in urine was not completed. Since it was not possible to detect a difference 
between the extracted derivatized and un-derivatized samples ion ratios, it was not possible to do 
a complete comparison study between the chiral column separation methods and the pre-column 
derivatization method. 
 The SPE extraction and derivatization steps for the pre-column derivatization separation 
method were very time-consuming when combined, averaging 5.5-6 hours. A forensic and/or 
clinical lab may wish to shorten the overall analysis time by potentially pairing the derivatization 
with a liquid-liquid extraction method, which may reduce overall bench time and possibly 
achieve detection of the derivatized analytes. 
 Due to time constraints, a complete validation study was not conducted for either chiral 
separation method, as per SWGTOX guidelines. The validation process would include carryover, 
interference studies, precision, and limit of detection and quantitation studies.38 
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5.5. Future Research 
 This study offers several opportunities for additional research. First, the author was 
unable to get the current derivatization process on the extracted urine samples to work, so was 
unable to detect derivatized samples on the instrument. A different derivatization process could 
be utilized, possibly paired with a different extraction method, or a different achiral column, 
could be analyzed in future research. 
 Second, an extensive qualitative analysis should be explored for the chiral column 
separation methods. Only 5 unknown urine samples from one sample batch, provided by the 
OSU-CLS lab, were tested over 3 days. More samples should be tested to determine if the overall 
efficiency of the SPE vs D & S separation methods supports or refutes the present study. 
 Finally, different populations of meth and/or amphetamine users could be investigated. 
This study focused on the application of clinical samples for drug therapy compliance, but 
antemortem and postmortem samples could also be analyzed. Examining positively confirmed 
urine samples from other patient clinics may also be beneficial. Different clinics in Oklahoma 
may yield different compliance results, which could indicate that a person claiming to be taking a 
legal form of meth or amphetamine, is really taking the illegal form of either drug, or some 
variation 
5.6. Conclusion 
 In conclusion, this study presents an option for forensic and clinical toxicology labs 
wishing to separate d- and l-enantiomers of meth and amphetamine in urine in-house without 
having to send these positively confirmed samples to an off-site lab for the testing to be done. It is 
important to note that any lab should consider the overall cost for materials, time, and effort, in 
addition to the analysis time length, when deciding which chiral separation method to employ.
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